Carter Robert Ross
Chief Financial Officer
Carter Robert Ross has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: May 22, 2026.
On the most recent filing, Carter Robert Ross is listed as Chief Financial Officer at Oncology Institute, Inc. Inside the rolling window, Carter Robert Ross reported no open-market purchases and 1 open-market sale totaling $879 in TOI.
Companies traded
Other insiders at TOI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$879
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Carter Robert Ross made?
Carter Robert Ross has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Carter Robert Ross trade?
Carter Robert Ross has filed SEC Form 4 disclosures for 1 company, including TOI.
When was Carter Robert Ross's most recent SEC Form 4 filing?
Carter Robert Ross's most recent SEC Form 4 filing on Tracefour is dated May 22, 2026.
What is Carter Robert Ross's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Carter Robert Ross is listed as Chief Financial Officer.
What is Carter Robert Ross's total buy and sell value in the current window?
Inside the rolling retention window, Carter Robert Ross bought $0 and sold $879 based on SEC Form 4 filings.
What was Carter Robert Ross's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 247 TOI shares on 2026-01-02, worth $879, per SEC Form 4 filings.